Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer.

Suppr

超能文献

作者信息

Di Fiore F, Charbonnier F, Lefebure B, Laurent M, Le Pessot F, Michel P, Frebourg T

出版信息

Br J Cancer. 2008 Aug 5;99(3):551-2. doi: 10.1038/sj.bjc.6604451. Epub 2008 Jul 1.

DOI:10.1038/sj.bjc.6604451

PMID:18594536

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2527802/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f990/2527802/0be1770ee5d5/6604451f1.jpg

相似文献

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer.

Br J Cancer. 2008 Aug 5;99(3):551-2. doi: 10.1038/sj.bjc.6604451. Epub 2008 Jul 1.

KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?

Br J Cancer. 2010 Mar 16;102(6):1074-5; author reply 1076-7. doi: 10.1038/sj.bjc.6605582. Epub 2010 Feb 16.

Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.

Ann Oncol. 2013 May;24(5):1267-73. doi: 10.1093/annonc/mds620. Epub 2013 Jan 4.

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.

Ann Oncol. 2017 Jun 1;28(6):1294-1301. doi: 10.1093/annonc/mdx112.

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.

Mol Cancer Ther. 2016 May;15(5):1106-12. doi: 10.1158/1535-7163.MCT-15-0820. Epub 2016 Apr 1.

The Developing Role of Anti-Epidermal Growth Factor Receptor Agents in the Treatment of Advanced or Metastatic Colorectal Cancer.

Oncology (Williston Park). 2017 Nov 15;31(11):785-8, 802.

KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.

Curr Cancer Drug Targets. 2010 Dec;10(8):813-23. doi: 10.2174/156800910793357989.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Cancer Res. 2006 Apr 15;66(8):3992-5. doi: 10.1158/0008-5472.CAN-06-0191.

Optimization of Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.

Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16.

[Molecular pathology analysis of the KRAS mutation status in patients with metastasized colorectal carcinoma: an initial approach using predictive pathology].

Pathologe. 2008 Feb;29(1):93-6. doi: 10.1007/s00292-007-0966-y.

引用本文的文献

Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients.

Oncotarget. 2017 May 26;8(44):77928-77941. doi: 10.18632/oncotarget.18272. eCollection 2017 Sep 29.

KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.

PLoS One. 2014 Aug 19;9(8):e104902. doi: 10.1371/journal.pone.0104902. eCollection 2014.

Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array.

J Transl Med. 2014 May 26;12:147. doi: 10.1186/1479-5876-12-147.

Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications.

Oncol Lett. 2013 Jan;5(1):249-254. doi: 10.3892/ol.2012.963. Epub 2012 Oct 10.

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.

Br J Cancer. 2010 Dec 7;103(12):1765-72. doi: 10.1038/sj.bjc.6606008. Epub 2010 Nov 23.

Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods.

J Mol Diagn. 2010 Jan;12(1):118-24. doi: 10.2353/jmoldx.2010.090081. Epub 2009 Dec 10.

本文引用的文献

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

J Clin Oncol. 2008 Jan 20;26(3):374-9. doi: 10.1200/JCO.2007.12.5906.

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

Ann Oncol. 2008 Mar;19(3):508-15. doi: 10.1093/annonc/mdm496. Epub 2007 Nov 12.

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.

Br J Cancer. 2007 Oct 22;97(8):1139-45. doi: 10.1038/sj.bjc.6604009. Epub 2007 Oct 16.

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

J Clin Oncol. 2007 Aug 1;25(22):3230-7. doi: 10.1200/JCO.2006.10.5437.

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

Br J Cancer. 2007 Apr 23;96(8):1166-9. doi: 10.1038/sj.bjc.6603685. Epub 2007 Mar 20.

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

Cancer Res. 2007 Mar 15;67(6):2643-8. doi: 10.1158/0008-5472.CAN-06-4158.

Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.

Int J Cancer. 2007 Jan 1;120(1):7-12. doi: 10.1002/ijc.22276.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Cancer Res. 2006 Apr 15;66(8):3992-5. doi: 10.1158/0008-5472.CAN-06-0191.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验